SkyscraperCity banner

1 - 20 of 122 Posts

11,781 Posts
Discussion Starter #1 (Edited)
Location: Little France

Value: £600m

Developer: Scottish Enterprise, NHS Lothian, The University of Edinburgh, Alexandria Real Estate Equities Inc

Architects: Keppie Design, Allan Murray Architects, Michael Laird Architects, BMJ Architects, Sheppard Robson, Oberlanders

100 acre bio-tech hub - Scotland's key initiative in the development of its life sciences industry.

Official Site: Edinburgh BioQuarter

Current Status: U/C (Phase 4 Proposed)

Initial BioQuarter masterplan by Keppie Design

Current BioQuarter development

1. Queens Medical Research Institute (QMRI) - relocated to BioQuarter in 2004, with 650 researchers working on projects related to inflammation, cardiovascular disease and reproductive health.

2. Site of the Royal Hospital for Sick Children, part of NHS Lothian's University Hospitals Division, a 600-bed paediatric facility offering a full range of acute, surgical, day - and acute care services planned to move to the BioQuarter Campus in 2016.

3. The Anne Rowling Regenerative Neurology Clinic - created with a £10m donation from author JK Rowling to develop new therapies for MS and related conditions.

4. University of Edinburgh Medical School - 250 researchers and clinical teaching staff working across the full range of medical conditions.

5. The Royal Infirmary of Edinburgh - a major 900-bed teaching hospital providing a full range of acute medical and surgical services for the Lothian region as well as specialist services for South-East Scotland.

6. Site of the Brain and Body institute (planned for 2016), bringing together 500 researchers in neuroscience, neurology and psychology on the BioQuarter site.

7. Nine - a three-story multiple occupancy building for life science companies from start-ups to major international businesses. Includes meeting rooms, an AV suite, restaurants, offices and laboratory facilities.

8. The Scottish Centre for Regenerative Medicine - 230 researchers working on stem cells and other regenerative therapies for conditions such as Parkinsons', Multiple Sclerosis, Diabetes and Motor Neurone Disease.

Nine by Michael Laird Architects
£24 million 10,000 square metres bio-incubator facility is dedicated to housing start-up companies and established pharmaceutical companies.

Scottish Centre for Regenerative Medicine (SCRM) by Sheppard Robson
£54 million 9,000 square metres facility, dedicated to the study and development of new regenerative treatments for human diseases.

Anne Rowling Regenerative Neurology Clinic by Keppie Design
£10 million state of the art research clinic.

BioQuarter future development concepts by Oberlanders (now superseded?)

BioQuarter Phase 4 Masterplan by Allan Murray Architects

In 2009, Scottish Enterprise purchased further land (Phase 4) to the south east to ease the pressure on earlier phases.

The EBQ Partners are now developing a new Masterplan for the whole of the Edinburgh BioQuarter.

To fulfil the ambition of the BioQuarter to become one of the top Life Sciences destinations in the world, a new masterplan is being developed to make sense of the Quarter as a whole and to create a new and vibrant part of the city - the kind of environment that will attract people to work in, stay in, and visit. It will complement the urban regeneration elsewhere in this part of the city, and enhance Edinburgh's network of green spaces with a new park and woodland.

The Scottish Government promotes better placemaking as one of its National Outcomes, encouraging the creation of "well-designed, sustainable places." These are "vitally important to the social, environmental and economic success of our cities". This is echoed in the City of Edinburgh Council's Standards for Streets, at the heart of which is an imperative to create "good public realm quality in a consistent manner across the city."

The purpose of the Masterplan is to create a cohesive whole, connecting the various parts of the Quarter together, and integrating it into its surroundings. It will create a coherent layout of streets, public spaces and landscapes within a flexible structure that can adapt to unknown future requirements. Masterplans like this need to be capable of incremental growth, and be flexible enough to accommodate change.


11,781 Posts
Discussion Starter #2
Edinburgh BioQuarter gains three new tenants

The Scotsman - 6th February, 2013

First Minister Alex Salmond has hailed the success of bringing businesses, hospitals and universities together on the BioQuarter site in Edinburgh after three more tenants yesterday signed up to take space on the fast-growing science park.

Regenerative medicine outfit R Biomedical and two support firms – patent attorney practice Marks & Clerk and science communication company Science Squared – have each rented space at Nine, the “bio-incubator” centre on the site built by Scottish Enterprise.

Swedish healthcare firm Molnlycke has also doubled the amount of office space it has rented in Nine having only opened its base at the BioQuarter six months ago.

Later in the day, a fourth firm – legal giant Maclay Murray & Spens – revealed it is also opening an office at the BioQuarter.

Salmond told The Scotsman: “In just one day, we’ve gone from seven to ten firms on this site. This demonstrates the benefits of bringing together Edinburgh Royal Infirmary, Edinburgh University’s medical school and these companies on the same site.”

During a tour of Nine, Salmond tested out an eye scanner made by I2eye Diagnostics, which will allow doctors to test the vision of young children and adults with learning difficulties. Scotland on Sunday revealed last month I2eye had won approval to sell its device in Europe and the United States.

Salmond was also shown an MRSA hospital super-bug testing kit being developed by Molnlycke, using technology licensed from Scottish Enterprise.

More than 600 companies are active within Scotland’s £3 billion life sciences sector, together employing 32,000 people. But many commentators have questioned why there are so many small firms and not more large businesses, employing hundreds of staff each.

Lena Wilson, chief executive of Scottish Enterprise, said: “Within ten years, I believe that we will be seeing more of those big employers in Scotland. But they won’t just be focused on the domestic market, they will be international in outlook.

“It’s not an either-or situation. If we grow from having 600 companies to 900 companies then some of those will be larger businesses.”

Rhona Allison, senior director of life and chemical sciences at Scottish Enterprises, added that it was important to attract support firms such as Marks & Clerk and Science Squared into developments such as BioQuarter.

“We need to create a support system for life science companies so that they want to set up in Scotland,” Allison said.

“So part of the work being done is to help professionals like patent attorneys set up on site so they can offer quick advice to businesses.”

News of the latest tenants at the BioQuarter came ahead of tomorrow’s Scottish Enterprise life sciences dinner.

11,781 Posts
Discussion Starter #3
Aquila BioMedical moves to Edinburgh BioQuarter

Business Insider - 26th August, 2013

Life sciences firm Aquila BioMedical has relocated to the new Nine business incubator building at Edinburgh BioQuarter.

The contract pharmaceutical research provider has moved from an academic laboratory space in the Queens Medical Research Institute to purpose-built Nine.

Aquila BioMedical joins 12 other firms already based at Nine, which opened last year.

The start-up, which launched in 2011, conducts industrial standard research with support from world-leading academic experts and clinicians, offering research models in the therapeutic areas of Multiple Sclerosis, Autoimmune Disease, Inflammation and Analgesia.

Aquila has also launched MBP-Tracker technology, developed with the support of a SMART: SCOTLAND award, and has completed a number of contracts from clients in Europe and the US utilising the platform.

Aquila BioMedical said the move to commercial facilities at the Bioquarter campus will play a key role in maintaining “these vital connections whilst creating independence and room for company growth”.

Chairman Dr Howard Marriage said: “The company is now preparing for a significant investment round to capture the promising start and exploit its growing international client base.

“With the continuous evolution of drug discovery to specialist expert external providers we are well placed to accelerate growth in 2014.

“The investment will expand the range of service offerings across multiple autoimmune diseases, introducing fibrotic disease and support with increasing use of human cell systems for mechanism of action and biomarker discovery.

“The team are very committed to bringing our service business model of high quality experimental systems with integrated academic insight in study design and data interpretation to the wider drug discovery community”.

Julia Brown, director of chemical and life sciences, Scottish Enterprise, added: " Our ambition for Edinburgh BioQuarter to become one of the world's leading hubs for life sciences is fast becoming a reality.

In just over a year since it officially opened, more than 80 per cent of the Nine incubator has already been taken over by innovative life sciences companies.

“We very much welcome Acquila to the community and look forward to working with the company to help realise its ambitious growth plans.”

11,781 Posts
Discussion Starter #4
Niddrie Burn restored to allow development opportunities for BioQuarter

The Edinburgh Reporter - 6th June, 2013

A major river restoration project was officially launched today, paving the way for future housing and other development in the Edinburgh BioQuarter.

The £11m Niddrie Burn Restoration Project saw 1.8km of the Niddrie Burn realigned to form a river corridor, with landscaping, footbridges and a flood storage area within parkland.

This complex engineering project, delivered on budget and jointly funded by the City of Edinburgh Council and Scottish Enterprise (£5.77m of the total budget), also required a number of public utilities to be diverted, including 1km of Scottish Water trunk sewer, 700metres of water trunk main and 240 metres of Scottish Power cables.

A new public transport link road has also been created and came into use earlier this week. This £2.75m road consists of 1km of carriageway connecting Little France Drive with Greendykes Road, with a 200m section that forms a bus lane for public transport, taxis and emergency vehicles only, enforced by a bus lane camera.

Councillor Lesley Hinds, Transport and Environment Convener, said: “Today is an important milestone for this fast-growing part of Edinburgh; the effects of this work will be enormously beneficial to the whole area. This complex engineering project, delivered on budget, has created a wealth of opportunities for new homes and new development in the BioQuarter. The new Link Road will also make it much easier for hospital staff, patients and visitors to travel to and from the Royal Infirmary and we’re looking forward to seeing a new bus service start operating on this road in the near future.”

Scottish Enterprise Life, Chemical Sciences and Company Growth Director, Rhona Allison, added: “Scottish Enterprise has jointly managed the Niddrie Burn restoration works and the extension to Little France Drive as part of the BioQuarter programme. Our focus is to help grow the Scottish economy by investing in projects that will create employment and enhance Scotland’s reputation as an attractive place to live, work and visit. The BioQuarter is being transformed by its partners into a top global destination for life science R&D, and effective transport provision is key to its success.

“We hope to double the working population at Little France by 2029 which will attract considerable private investment at the BioQuarter: today’s announcement builds on the continuing delivery of world class facilities that will maintain Scotland’s high profile in this critical industry sector.”

Hugh Rutherford, Chair of the Edinburgh Business Forum, said: “Development and regeneration is one of the key elements of the Economic Strategy that the City of Edinburgh Council and the Edinburgh Business Forum are committed to delivering over the next four years. This is a great example of partnership working that is going to have a massive impact on this area of Edinburgh.”

The link road project also incorporates a 2m footpath and a 4m combined footpath / cycleway and street lighting.

Archaeological surveys were carried out as part of the project and the remains of an 18th century ice house were discovered among other finds from the former Niddrie Marischal Estate.

Design of the RIE Link Road was by City of Edinburgh Council, while Jacobs Engineering were responsible for design and site supervision of the Niddrie Burn Restoration Project. The main contractor on the project was Carillion.
A competition was run by the Portobello and Craigmillar Neighbourhood Partnership to choose a new piece of public art for the area; details of this project will be unveiled soon.

Azeri Dragon
6,397 Posts
Fantastic. Another masterpiece in Edinburgh. I wish we had similar thing in Glasgow

11,781 Posts
Discussion Starter #6
Edinburgh BioQuarter announces partnership with Lilly

Edinburgh Bioquarter - 21st October, 2013

A Transatlantic partnership will bring University of Edinburgh academics together with global pharmaceutical Eli Lilly and Company, based in Indiana, US, to collaborate on novel cancer mechanisms.

Edinburgh BioQuarter has today announced a collaborative partnership between the University and Lilly.

Under the terms of the agreement, the Edinburgh Cancer Discovery Unit (ECDU) will provide Lilly with access to the EDCU’s highly specialized biology models to potentially gain additional insight into the mechanism of action for select Lilly oncology compounds.

Neil Carragher, Principal Investigator for the Edinburgh Cancer Research Centre, said: “The collaboration with Lilly provides an excellent opportunity to partner the latest innovations in cancer research from the Edinburgh Cancer Discovery Unit with select compounds from Lilly’s oncology pipeline.”

“Lilly is pleased to partner with the Edinburgh Cancer Discovery Unit and leverage its new cancer models and technical capabilities,” said Elaine Sullivan, vice president of global external research and development at Lilly. “Lilly’s external innovation strategy comprises a diverse set of collaborations developed with the goal of accelerating the delivery of breakthrough medicines to patients with unmet needs.”

Diane Harbison, Head of Business Development at Edinburgh BioQuarter, said: “Edinburgh BioQuarter is currently involved in a number of significant collaborations. Following on from a partnership with Galapagos NV, our recently announced collaboration with Biogen Idec and our longstanding association with GSK, this new strategic alliance further demonstrates the industry’s growing awareness of the depth of world-class translational research being undertaken here in Edinburgh.”

11,781 Posts
Discussion Starter #7
Edinburgh BioQuarter announces Johnson & Johnson Innovation ‘touchdown’ at Nine

Edinburgh BioQuarter - 9th December, 2013

International pharmaceutical company Johnson & Johnson Innovation will be ‘touching down’ at ‘Nine’, Edinburgh BioQuarter.

Johnson & Johnson Innovation will take up a virtual tenancy via a partnering office within the Edinburgh BioQuarter’s flagship multi occupancy and business incubation building, Nine, from January 2014.

A virtual tenancy at Nine, minimises occupation costs but allows Johnson & Johnson Innovation use of Nine’s first class facilities whilst integrating into network of experts and stimulating innovative thought through association with the world class research at the University of Edinburgh and associated science facilities.

'Nine', an 85,000 sq ft multi-occupancy building, which opened in 2012, offers office, laboratory and meeting room space for both newly formed companies and established leaders in the biopharmaceutical industry seeking close proximity to the clinical research on the BioQuarter site. Investors and ideas can come together in a location that combines some of the best medical research in the world with two major hospitals, dedicated bio-incubator facilities and an outstanding team of business development personnel.

Diane Harbison, Head of Business Development at Edinburgh BioQuarter, said: “The Johnson & Johnson Innovation virtual office means that we will have representatives from the Johnson & Johnson Innovation Centre on the same site as our researchers and clinicians, enabling us to increase our interactions with them and hopefully increase our level of engagement.

“We look forward to collaborating with Johnson & Johnson Innovation and hope that we can increase their awareness of the opportunities available at BioQuarter and in the rest of Scotland.”

Julia Brown, Director of Life and Chemical Sciences, said: "Scottish Enterprise welcomes the news that Johnson & Johnson Innovation is joining the community at Nine.

"Scotland's life sciences industry already contributes more than £3 billion a year to the Scottish economy and this is targeted to double by 2020. Attracting global companies like Johnson and Johnson Innovation to be part of our innovative life sciences community at EBQ is a key element of our industry strategy."

11,781 Posts
Discussion Starter #8 (Edited)
Edinburgh BioQuarter guidance agreed

City of Edinburgh Council - Planning News, Winter 2013

Supplementary Guidance to support the development of ’The Edinburgh BioQuarter’ and the South East Wedge Parkland was agreed by Planning Committee on 5 December.

The guidance supports the development of the Edinburgh BioQuarter as a top 10 global centre of excellence for life sciences with the potential to create a significant number of jobs. The guidance sets out a vision for the creation of a mixed use, urban quarter which protects and enhances the landscape setting of the city.

Planning Committee also approved a draft masterplan for the BioQuarter. This builds on the principles set out within the approved supplementary guidance with a key masterplan diagram which defines the location of development, access, key frontages and landscape retention. The draft masterplan also sets out detail in regards to place making, density, building heights, landscape impact, transport and flooding and drainage.

Consultation on the draft masterplan will start on 6 January for a period of 8 weeks. It is intended to report the finalised masterplan to Planning Committee in May 2014.
Edinburgh BioQuarter Non-Statutory Masterplan draft for consultation


11,781 Posts
Discussion Starter #9
BioQuarter director reveals his hopes for Edinburgh firm as they make inroads to battle diseases and continue to grow

Daily Record - 24th January, 2014

MIKE Capaldi is helping to establish Edinburgh as one of the world’s leading hubs for translating biomedical research into commercial products.

“We’re one of the leading campuses anywhere in Europe for translational medicine,” Capaldi explains of Edinburgh BioQuarter, where he is director of commercialisation.

“That means getting ideas out of the research lab and getting them into humans to test them as quickly as we can. We work with the University of Edinburgh’s College of Medicine and Veterinary Medicine and we work with NHS Lothian to identify, build and spin out companies. The idea is to help academics and clinicians get more commercially-minded. It’s going to be a huge campus. It’s a 25 year project and there will eventually be two hospitals here, four to five research institutes and a bunch of biotech and pharmaceutical companies working together with shared resources and a shared vision.”

Based at Little France, to the south of Edinburgh alongside the Royal Infirmary of Edinburgh and Edinburgh University’s world-renowned medical school, Edinburgh BioQuarter is a 100-acre science campus that aims to accelerate the development of new treatments for human diseases.

The project is a partnership between Scottish Enterprise, the University of Edinburgh, NHS Lothian and California-based life sciences property specialist Alexandria Real Estate Equities, and is expected to generate £250m of investment over the next 15 years.

“Revenues into life sciences in Scotland are about £3bn a year at the moment and the Scottish Government wants that to double to double to £6bn by 2020,” Capaldi explains. “Edinburgh BioQuarter is the Scottish Government’s biggest programme in the life sciences arena so it’s expected to deliver its share of that growth. We’re actually going to create 6000 jobs on this site over the course of the programme. That’s a big contributor to the local and national economies and the life sciences industry.”

When Capaldi joined BioQuarter in 2010, Edinburgh University’s College of Medicine was receiving about £5m a year in translational medicine funding. Last year it was about £22m. Funding from industrial collaborations has grown similarly in scale, with a resulting uplift in spin-out activity. “In the five years before BioQuarter started, only one biotech company was spun out of Edinburgh University’s College of Medicine,” Capaldi says.

“The team and myself have been in place for three and a half years and we’ve spun out seven companies. Another four to five companies are in the pipeline.”

Bioquarter’s successes include i2eye Diagnostics, developers of the world’s first visual field analyser for children and vulnerable adults, and Aquila Biomedical, a pre-clinical contract research organisation for central nervous system and neurological disorders.

“One of the companies we’re going to spin out in the next three months developed a completely new type of medical diagnostic imaging using fibre optic cable,” Capaldi says. “This can be put into the lung and used to inject nano amounts of fluorescent compound that measure biological events. For example, it’s very common for patients on intensive care ventilators to get a lung infection. It’s difficult to know what’s going on in these situations, but using this device, the fluorescent compound will light up, helping to diagnose the cause of the problem.”

Edinburgh BioQuarter is home to the £54m Scottish Centre for Regenerative Medicine, a centre of excellence in stem cell therapies that allow the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. Harry Potter author JK Rowling, whose mother Anne died of multiple sclerosis, also helped fund the Anne Rowling Regenerative Neurology Clinic, which is exploring new therapies for multiple sclerosis and related conditions. New research centres planned on site include The Brain and Body Institute (2016), while the new Royal Hospital for Sick Children is due on site from 2017.

“We’re very good at inflammatory disease such as rheumatoid arthritis and reproductive health,” Capaldi says. “We’re good in cardiovascular diseases and another area of expertise on this site is liver and kidney disease. We have Scotland’s national liver and kidney transplant centres here so there’s a lot of physical research in that area.”

The son of a GP and a physiotherapist, Capaldi was destined to follow a career in healthcare or medicine. After a BSc in biological sciences at the University of East Anglia and a PhD in medical biophysics at Manchester University, he spent 26 years in research and commercial roles in the pharmaceutical and life sciences industries across the US and Europe.

His first experience of Scotland was in the late 1990s, when he helped to float Core Group, an early biotech pioneer based in Kilmarnock that specialised in re-purposing out-of-patent drug technologies.

“We were looking to raise £20m at flotation, but by the time we’d been round the City and done our pitch, we had £125m on the table,” Capaldi recalls. “Investors had seen what had happened in the US and wanted to be part of the new era of biotech in the UK.”

Capaldi went on to see the biotech boom disappear when the dot-com crash arrived just as he took up his first chief executive’s role at Oxford University spin-out Synaptica. He nonetheless helped to raise £4m venture capital for the business and is still a non-executive director. Capaldi’s last chief executive’s role before joining Edinburgh BioQuarter was with Hunter-Fleming, which was developing new pharmaceuticals for inflammatory degenerative diseases.

Capaldi’s ultimate goal is to help Edinburgh BioQuarter become self-funding.

“Our funding dries up in March 2015 and from that point we’re expected to be sustainable in some way,” he explains. “So we’re changing our business model and going back to what I’ve done before – we’re going to turn ourselves into a company with a medium term aim of doing an IPO and raising money through the markets. If we IPO and raise money, we can bring investment with us and become a venture capitalist, so we won’t just identify and spin out these companies, we’ll fund them as well.”

11,781 Posts
Discussion Starter #11
Medical start-up EMI moves in to BioQuarter

Scotland on Sunday - 17th August, 2014

A start-up company working to speed up the diagnosis of lung diseases will this week move into new offices and laboratory space following a successful £4 million fund-raising.

Edinburgh Molecular Imaging (EMI) is taking 2,300 square feet at Edinburgh’s BioQuarter following the deal, which gives venture capital (VC) fund Epidarex a majority stake in the business. EMI is also recruiting two additional senior members of staff.

Epidarex, Scotland’s first new life science VC firm in more than a decade, recently closed a £47.5m fund dedicated to UK start-ups. Backers *include European Investment Fund, Scottish Enterprise, the Strathclyde Pension Fund, US drug giant Eli Lilly, King’s College London and other major research universities.

Spun out at the start of this year, EMI is based on the work of Dr Kev Dhaliwal and professors Mark Bradley and Christopher Haslell from Edinburgh University’s college of *medicine. They have created a process for “marking” specific diseases which can then be picked up by scanners and other imaging equipment.

Ian Wilson, EMI’s senior technology officer, said this could cut the time it takes to diagnose a disease from 48 hours to two hours or less. This would aid in managing an array of complex diseases such as lung cancer, fibrosis, respiratory infections and acute respiratory distress syndrome.

“It is very hard to know sometimes whether a lung *disorder is still active or not,” he said. “Long intervals to *diagnose a disease delays treatment, and for intensive care patients this can lead to death.”

Recruited to head the newly formed EMI, Wilson spent the past two years working with Xstrahl, a multinational *designer and developer of X-ray equipment. Before that he spent 18 years with US conglomerate GE, where he was latterly head of biology based out of London.

The £4m from Epidarex will fund clinical development of a lung cancer application and Phase II trials of a diagnosis for bacterial infection for two years. Advisers to EMI on the deal included Johnston Carmichael.

Shaun Millican, the firm’s head of technology and life sciences, said: “The emergence of venture capital groups like *Epidarex Capital, which has based its operations in Edinburgh, is a welcome development which bodes well for the sector.”

11,781 Posts
Discussion Starter #12
From Invest Edinburgh:

Hotel Opportunity: Edinburgh BioQuarter

Hotel development opportunity exists for an internationally branded 4 star 120 bed hotel with associated, leisure, meeting room and restaurant facilities. Car parking will be within adjacent multi storey car park.


Edinburgh BioQuarter is an academic medical centre with a focus on interdisciplinary research and translational medicine. The campus brings together clinicians, industrialists, patients, scientists, state-of-the-art pre-clinical and clinical research facilities, and an academic teaching hospital on one campus.

Extending to more than 100 acres, Edinburgh BioQuarter is a £600m joint venture between Scottish Enterprise, the University of Edinburgh and NHS Lothian.

Once fully developed, the BioQuarter will offer up to 1.4m sq ft (130,063sq m) of specialist accommodation for academic, commercial and healthcare activity.


Edinburgh BioQuarter is situated on the principal A7 arterial route which links the city centre to the A720 city bypass. The BioQuarter campus is well served by public transport, with numerous bus routes from locations across the city. A “Park & Ride” facility with 900 car spaces is located on the City Bypass within two miles, with bus services running past the BioQuarter every ten minutes.

Waverley Station, Edinburgh’s main rail hub, is three miles to the south of our campus at the heart of the city centre, and Edinburgh Airport is situated 11 miles to the west of BioQuarter.

Edinburgh is connected across the UK and internationally, with principal international destinations accessible either via direct flights or through London’s five airports, all approximately one hour’s flying time from Edinburgh.


Hotel Development Opportunity exists for an internationally branded 4 star, 120 bed hotel with associated, leisure, meeting room and restaurant facilities. Car parking will be within adjacent multi storey car park.

- See more at:

11,781 Posts
Discussion Starter #13
£25.7m to create research powerhouse

University of Edinburgh - 25th March, 2015

A £25.7 million funding boost will advance biological research and aid the quest for new therapies to treat damaged tissues.

The investment by the UK Government will enable the University of Edinburgh to create a new biology complex with world-leading laboratory space for 350 researchers and to establish a new Centre for Tissue Repair.

The two projects are the only Scottish bids to secure funding in a fiercely competitive round of awards from the UK Research Partnership Infrastructure Fund.

More than £50 million has been leveraged from industry, charity and philanthropic funds to double-match the investment.

Biology boost

An investment of £15m will help to create a research complex that integrates three research areas with an advanced technology hub to transform how biology is investigated. A key part of its focus will be infection and global health.

Another vital component will be synthetic biology, which creates artificial biological systems that can be used by industry and in medical research. They could also aid the discovery of new drugs.

Scientists will also focus on epigenetics - studying how genes can be modified without a change to the DNA sequence.

The new biology complex will include facilities for community engagement.

Centre for Tissue Repair

A second investment of £10.7 million will enable the creation of a Centre for Tissue Repair, bringing together experts in inflammation and scarring, and tissue regeneration.

Researchers hope to discover and deliver new treatments for tissue damage, such as the destruction of nerve cells in multiple sclerosis or damage to the liver caused by infections.

The Centre will provide a platform to investigate the mechanisms underlying tissue injury.

Advanced imaging and sensing technologies will be developed that will enable researchers to view and measure tissue regeneration in real time.
Such techniques will be critical for helping researchers to evaluate the effectiveness of new treatments in clinical trials.

11,781 Posts
Discussion Starter #14
£300,000 for new paths through Little France Park

Edinburgh Innertube Map - 28th April, 2015

Transport Scotland, via the Sustrans Community Links Fund, has awarded ELGT £300,000 towards the design and implementation of a new high-quality walking and cycling route through what will become Little France Park – currently under development.

Running through the new park, behind the Bioquarter and the Royal Infirmary, the new route will link the new and proposed housing developments in the south east of the city and beyond to the city centre and Craigmillar. It will hopefully become a core cycling and walking route, linking the new neighbourhoods as they come on stream to existing residential and employment areas as well as the new Shawfair railway station on the Borders rail line.

The parkland is a key piece of green infrastructure for the city and region and a crucial regeneration tool linking local communities – including Craigmillar, Greendykes and Niddrie to employment opportunities. A feasibility and implementation study of the parkland was completed in 2013 which proposed four key character areas. This project will deliver the first phase of the parkland by introducing links to encourage the use of the area for informal sports and events and formalising existing paths in order to link with housing developments, a proposed new town centre in Craigmillar, a new cycling facility proposed adjacent to the Jack Kane Centre, employment prospects at the Royal Infirmary and the Edinburgh BioQuarter, medical facilities and the existing school.

The proposed Parkland will also connect and realign disjointed existing paths. This is a great opportunity to create a new landscape setting for the city providing opportunities for outdoor recreation which brings social and health benefits to this area. The parkland will be an important part of the green network, providing a focus for local and sub-regional leisure and amenity, improved connectivity and enhanced biodiversity.

11,781 Posts
Discussion Starter #15
Positive signs at BioQuarter. Application submitted for temporary modular lab/office accommodation to satisfy demand from new tenants as a stopgap while the next large multi-occupancy building is designed and constructed (still 2 years away apparently).

15/02579/AMC | Application for matters specified in conditions of planning permission in principle 02/04372/OUT relates to Conditions 2, 3, 4, 5 and 6 of 13/05048/FUL for 2 no. modular office buildings, associated car parking and amended vehicular access arrangements. | Land 267 Metres Northeast Of 399 Old Dalkeith Road Edinburgh

3,167 Posts
Positive signs at BioQuarter. Application submitted for temporary modular lab/office accommodation to satisfy demand from new tenants as a stopgap while the next large multi-occupancy building is designed and constructed (still 2 years away apparently).

15/02579/AMC | Application for matters specified in conditions of planning permission in principle 02/04372/OUT relates to Conditions 2, 3, 4, 5 and 6 of 13/05048/FUL for 2 no. modular office buildings, associated car parking and amended vehicular access arrangements. | Land 267 Metres Northeast Of 399 Old Dalkeith Road Edinburgh
Definitely positive. Building Nine is over 50,000 square feet so I didn't expect it to fill up this quickly. SE has obviously been wrongfooted a bit by demand if the next building is 2 years away. The kind of occupants they attract tend to be headcounts in the tens and while the jobs are high value, it doesn't quickly spawn big players.

I still think it will be a very long term project to build up critical mass here - but alongside other initiatives across Scotland, it is one area that I think is worth the effort.

11,781 Posts
Discussion Starter #17
Drug discovery firm IOmet Pharma sold in $400m deal

BBC News - 13th January, 2016

Scottish drug discovery company IOmet Pharma has been bought by US pharmaceutical group MSD in a deal worth up to $400m (£280m).

Edinburgh-based IOmet specialises in the discovery and development of small molecules for the treatment of cancer.

The company's focus is in cancer immunotherapy and cancer metabolism.

Under the terms of the sale, IOmet will become a wholly-owned subsidiary of MSD, which is known as Merck in North America.

The total amount MSD will pay for IOmet is subject to the Scottish-based firm achieving agreed "milestones".

Eric Rubin, from MSD Research Laboratories, said: "By harnessing the power of the immune system, we are already witnessing great advancements in the treatment of cancer.

"The acquisition of IOmet is a further example of MSD's commitment to fully realising the potential of this rapidly evolving field through our existing innovative portfolio as well as the acquisition of promising immunotherapeutic candidates."

Deputy First Minister John Swinney said: "The Scottish government strongly supports the life sciences sector in Scotland and this news is testament to the intellectual vibrancy and strong commercial attractiveness of Scotland's life science businesses."

11,781 Posts
Discussion Starter #18
Tender notice reveals the next phase of development - £32m Institution for Regeneration and Repair (IRR) plus £4.2m of infrastructure improvements to the wider BioQuarter site - construction anticipated from April 2017.

Project Objective - IRR Building

The University of Edinburgh has recently completed its 4th building at the Edinburgh BioQuarter Campus the Chancellor’s Building, Queen’s Medical Research Institute (QMRI), Scottish Centre for Regenerative Medicine (SCRM) and Anne Rowling Regenerative Neurology Clinic (ARRNC). Similar to previous developments, the IRR will be critical to the College of Medicine & Veterinary Medicine’s future business strategy. The project has 3 primary objectives;

- Facilitate the relocation of final elements of the College’s business from the Central Area
- Accommodate the on-going expansion of the College’s research business
- Deliver core College facilities to offer collaboration and staff facilities.

The strategic objective of Phase 1 relates to the Construction of the new Institute for Regeneration and Repair building with TRF and Gym.

The IRR will offer laboratory and support space for 250 researchers with seminar, cafe and TRF facilities. A 400sqm gym will be located within the building envelope but operated independently from IRR.

Phase 2 - BioQuarter Infrastructure (phase A)

The strategic objective of Phase 2 will enable estates via our Edinburgh BioQuarter Infrastructure programme of Works to deliver an Exhibition Walk, pedestrian link to the Edinburgh Royal Infirmary and to provide an element of landscaped public realm at the IRR.

Phase 2 will offer the primary pedestrian and cycle route through the BioQuarter, connecting the existing and future development and fostering collaboration between the words class research buildings and facilities.

11,781 Posts
Discussion Starter #19
Pharma leader makes new Scottish research investment

Scottish Development International - 6th July 2016

Scotland has further strengthened its position as a global centre for medical research as Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, makes a major research Investment in a new Centre for Dementia Prevention in Edinburgh’s BioQuarter. The centre will be focussing its efforts - the CHARIOT study - led by the University of Edinburgh and Janssen R&D, on clinical trials to better understand and ultimately develop new treatments for Alzheimer’s disease.

Janssen R&D will be joining the 650 or so researchers and 20+ companies already active on the 100 acre BioQuarter site in south west Edinburgh. This key site for life sciences in Scotland has rapidly attracted both local and global companies. All are keen to work together on a location that more easily allows academics, clinicians and industry to collaborate, accelerating the translation of medicine from bench to bedside.

Welcoming the newcomer to the BioQuarter, Julia Brown, Life and Chemical Sciences Director at Scottish Enterprise, said: "This collaboration and new facility puts Scotland and the Edinburgh BioQuarter squarely on the map as an international innovation hub."

Naturally, Scotland’s talent has been a key magnet for Janssen R&D too. In this case, the expertise of Professor Craig Ritchie, the University of Edinburgh’s Professor of the Psychiatry of Ageing, and co-director of the new Centre. Professor Ritchie moved from his post at the Centre for Mental Health at Imperial College London in 2014, and is a leader on clinical trials in dementia. He leads the EPAD dementia consortium, an IMF-funded initiative to set up a network of European trial delivery centres, work that is led from Edinburgh by the University.

“By understanding how the brain ages over time, it may be possible to detect the earliest stages of dementia before symptoms develop. We hope this insight will lead to the development of new treatments that could prevent the disease in those at risk.”

Janssen R&D will also be able to take advantage of the wider expertise offered at the BioQuarter around clinical trials, translational medicine and rapid access to patients.

Janssen R&D’s investment has been underpinned by a £2.5 million building, the facility for clinical trials. It was funded, procured and constructed by Scotland’s main economic development agency, Scottish Enterprise. It’s just one of the ways that they can support inward investors looking to take advantage of Scotland’s competitive edge.
1 - 20 of 122 Posts